Biocardia Inc Asset Resilience Ratio
Biocardia Inc asset resilience ratio. Biocardia Inc (BCDA) has an Asset Resilience Ratio of 11.34% as of September 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BCDA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biocardia Inc (1998–2004)
Asset resilience ratio of Biocardia Inc from 1998 to 2004. This chart shows how Biocardia Inc's Asset Resilience Ratio has changed over time. Read BCDA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biocardia Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Biocardia Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.80 Million | 11.34% |
| Total Liquid Assets | $1.80 Million | 11.34% |
Asset Resilience Insights
- Moderate Liquidity: Biocardia Inc has 11.34% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Biocardia Inc Industry Peers by Asset Resilience Ratio
Compare Biocardia Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biocardia Inc Asset Resilience Ratio by Year (1998–2004)
Biocardia Inc asset resilience ratio by year from 1998 to 2004. The table below shows the annual Asset Resilience Ratio data for Biocardia Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2004-12-31 | 31.49% | $537.19K | $1.71 Million | +24.63pp |
| 2003-12-31 | 6.85% | $181.06K | $2.64 Million | -3.94pp |
| 2002-12-31 | 10.79% | $319.60K | $2.96 Million | +1.17pp |
| 2001-12-31 | 9.62% | $402.81K | $4.19 Million | +1.53pp |
| 2000-12-31 | 8.09% | $601.19K | $7.43 Million | -4.41pp |
| 1999-12-31 | 12.50% | $400.00K | $3.20 Million | +2.74pp |
| 1998-12-31 | 9.76% | $400.00K | $4.10 Million | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more